Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

San Francisco, California–based Genentech, has potent antitumor activity. More than half the patients with advanced and inoperable skin cancer treated with GDC-0449 responded to treatment (New Engl.

Genentech raised nearly $2 billion during its second initial public offering (IPO) on July 20 when Roche Holding refloated part of the company after acquiring all outstanding shares in June ...